The global cardiac amyloidosis market is poised for substantial growth, driven by rising prevalence and awareness of amyloidosis-related cardiac conditions. Characterized by amyloid protein deposition ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

AstraZeneca’s (NYSE:AZN) rare disease division, Alexion, announced that its experimental treatment anselamimab did not ...

New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...